Clinical Trial Update: Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating nilotinib in cognitively impaired Parkinson's disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies
• Parkinson Disease
• Parkinson Disease Dementia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Georgetown University | Conditions: Parkinson's Disease, Parkinson's Disease Dementia | Phase 1 | Status: COMPLETED